Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women

21. marts 2017 opdateret af: GlaxoSmithKline

A Phase III Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of the 30 mg Intravenous Formulation of the Neurokinin-1 Receptor Antagonist GW679769 for Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis

This study is being conducted to see if adding GW679769 (casopitant) to ZOFRAN will significantly decrease the number of patients who experience nausea and vomiting after surgery.

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

515

Fase

  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Aalst, Belgien, 9300
        • GSK Investigational Site
      • Brasschaat, Belgien, 2930
        • GSK Investigational Site
      • Bruxelles, Belgien, 1200
        • GSK Investigational Site
      • Gent, Belgien, 9000
        • GSK Investigational Site
    • Ontario
      • Toronto, Ontario, Canada, M5G 2M9
        • GSK Investigational Site
      • Toronto, Ontario, Canada, M5G 1X5
        • GSK Investigational Site
    • Quebec
      • Sainte-Foy, Quebec, Canada, G1V 4G2
        • GSK Investigational Site
      • Sherbrooke, Quebec, Canada, J1H 5N4
        • GSK Investigational Site
      • Moscow, Den Russiske Føderation, 101000
        • GSK Investigational Site
      • Moscow, Den Russiske Føderation, 111538
        • GSK Investigational Site
      • Moscow, Den Russiske Føderation, 117152
        • GSK Investigational Site
      • Perm, Den Russiske Føderation, 614107
        • GSK Investigational Site
      • St. Petersburgh, Den Russiske Føderation, 192242
        • GSK Investigational Site
      • Manila, Filippinerne, 1000
        • GSK Investigational Site
      • Quezon, City, Filippinerne, 1104
        • GSK Investigational Site
    • Alabama
      • Fairhope, Alabama, Forenede Stater, 36532
        • GSK Investigational Site
      • Mobile, Alabama, Forenede Stater, 36608
        • GSK Investigational Site
      • Montgomery, Alabama, Forenede Stater, 36106
        • GSK Investigational Site
    • Arkansas
      • Little Rock, Arkansas, Forenede Stater, 72205
        • GSK Investigational Site
    • California
      • Arcadia, California, Forenede Stater, 91007
        • GSK Investigational Site
      • Glendale, California, Forenede Stater, 91206
        • GSK Investigational Site
      • Laguna Hills, California, Forenede Stater, 92653
        • GSK Investigational Site
      • Pasadena, California, Forenede Stater, 91105
        • GSK Investigational Site
    • Florida
      • Boca Raton, Florida, Forenede Stater, 33067
        • GSK Investigational Site
      • Melbourne, Florida, Forenede Stater, 32901
        • GSK Investigational Site
      • Miami, Florida, Forenede Stater, 33143
        • GSK Investigational Site
      • West Palm Beach, Florida, Forenede Stater, 33409
        • GSK Investigational Site
    • Illinois
      • Chicago, Illinois, Forenede Stater, 60637
        • GSK Investigational Site
    • Kansas
      • Kansas City, Kansas, Forenede Stater, 66160
        • GSK Investigational Site
    • Maryland
      • Baltimore, Maryland, Forenede Stater, 21229-5299
        • GSK Investigational Site
    • Michigan
      • Royal Oak, Michigan, Forenede Stater, 48073
        • GSK Investigational Site
    • New York
      • Mineola, New York, Forenede Stater, 11501
        • GSK Investigational Site
      • New Hyde Park, New York, Forenede Stater, 11040
        • GSK Investigational Site
      • New York, New York, Forenede Stater, 10038
        • GSK Investigational Site
    • North Carolina
      • Winston-Salem, North Carolina, Forenede Stater, 27103
        • GSK Investigational Site
    • Ohio
      • Cincinnati, Ohio, Forenede Stater, 45208
        • GSK Investigational Site
    • Oklahoma
      • Oklahoma City, Oklahoma, Forenede Stater, 73104
        • GSK Investigational Site
    • Virginia
      • Charlottesville, Virginia, Forenede Stater, 22908
        • GSK Investigational Site
      • Winchester, Virginia, Forenede Stater, 22601
        • GSK Investigational Site
    • Washington
      • Seattle, Washington, Forenede Stater, 98195
        • GSK Investigational Site
      • Kwun Tong, Hong Kong
        • GSK Investigational Site
      • Pokfulam, Hong Kong
        • GSK Investigational Site
      • Shatin, New Territories, Hong Kong
        • GSK Investigational Site
      • Sheung Shui, New Territories, Hong Kong
        • GSK Investigational Site
      • Lahore, Pakistan
        • GSK Investigational Site
      • Badalona, Spanien, 08916
        • GSK Investigational Site
      • Barcelona, Spanien, 08025
        • GSK Investigational Site
      • Barcelona, Spanien, 08035
        • GSK Investigational Site
      • Barcelona, Spanien, 08003
        • GSK Investigational Site
      • La Coruña, Spanien, 15006
        • GSK Investigational Site
      • Mataro, Spanien, 08034
        • GSK Investigational Site
      • Pamplona, Spanien, 31008
        • GSK Investigational Site
      • Santiago de Compostela, Spanien, 15706
        • GSK Investigational Site
      • Bangkok, Thailand
        • GSK Investigational Site
      • Brno, Tjekkiet, 625 00
        • GSK Investigational Site
      • Jihlava, Tjekkiet, 586 01
        • GSK Investigational Site
      • Olomouc, Tjekkiet, 775 20
        • GSK Investigational Site
      • Pardubice, Tjekkiet, 532 03
        • GSK Investigational Site
      • Praha 2, Tjekkiet, 128 51
        • GSK Investigational Site
      • Praha 5, Tjekkiet, 150 08
        • GSK Investigational Site
    • Baden-Wuerttemberg
      • Freiburg, Baden-Wuerttemberg, Tyskland, 79110
        • GSK Investigational Site
    • Hessen
      • Marburg, Hessen, Tyskland, 35043
        • GSK Investigational Site
    • Mecklenburg-Vorpommern
      • Neubrandenburg, Mecklenburg-Vorpommern, Tyskland, 17036
        • GSK Investigational Site
      • Rostock, Mecklenburg-Vorpommern, Tyskland, 18059
        • GSK Investigational Site
      • Schwerin, Mecklenburg-Vorpommern, Tyskland, 19055
        • GSK Investigational Site
      • Wismar, Mecklenburg-Vorpommern, Tyskland, 23966
        • GSK Investigational Site
    • Rheinland-Pfalz
      • Ludwigshafen, Rheinland-Pfalz, Tyskland, 67063
        • GSK Investigational Site
    • Saarland
      • Homburg, Saarland, Tyskland, 66421
        • GSK Investigational Site
    • Sachsen-Anhalt
      • Halle, Sachsen-Anhalt, Tyskland, 06120
        • GSK Investigational Site
    • Schleswig-Holstein
      • Kiel, Schleswig-Holstein, Tyskland, 24105
        • GSK Investigational Site

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Kvinde

Beskrivelse

Inclusion criteria:

  • History of PONV (postoperative nausea and vomiting) and/or motion sickness.
  • Have not smoked for the last 6 months.
  • Having certain abdominal, breast, thyroid or shoulder surgery.

Exclusion criteria:

  • Pregnant or breastfeeding.
  • Have certain pre-existing medical conditions or take certain medications.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Forebyggelse
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Dobbelt

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Number of participants who achieved a complete response
Tidsramme: Up to 24 hours
Complete response defined as no vomiting or retching and no rescue therapy during the first 24 hours following placement of the last suture/staple. Vomiting defined as the forceful expulsion of gastrointestinal contents through the mouth or nose. Retching defined as the labored, spasmodic, rhythmic contraction of the respiratory and abdominal muscles in an attempt to vomit that is not productive of gastrointestinal contents (also known as "dry heaves"). Study participants who receive antiemetic rescue medication(s) during the initial 24 hours was considered treatment failures.
Up to 24 hours

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
The severity of nausea experienced by participants in each cohort during the 2, 6, 24 and 48 hour periods, as assessed by an 11-point, linear, numerical rating scale referred to as a "0-10 Likert scale"
Tidsramme: Up to 48 hours
Nausea is defined as a subjectively unpleasant sensation associated with the awareness of the urge to vomit; the desire to vomit without the presence of expulsive muscular movements. Each participant completed a Likert scale at 2, 6, 24 and 48 hours after placement of the last suture/staple. The Likert scale used a range of 0-10, where 0 = no nausea and 10 = nausea as bad as it could be.
Up to 48 hours
The severity of nausea experienced by participants in each cohort during the 2, 6, 24 and 48 hour periods, as assessed by a categorical scale (none, mild, moderate or severe), as defined in the protocol
Tidsramme: Up to 48 hours
Nausea is defined as a subjectively unpleasant sensation associated with the awareness of the urge to vomit; the desire to vomit without the presence of expulsive muscular movements. Each participant completed a categorical scale at 2, 6, 24 and 48 hours after placement of the last suture/staple. In the categorical scale, each participant asked to rate the severity of nausea as, none: no nausea, mild: queasiness/upset stomach that is manageable and minimally (if at all) affects daily activities, moderate: increased queasiness, sometimes with the feeling of having to vomit (but not vomiting), that has a significant negative effect on daily activities (for example, being unable to work, eat and drink, prepare food, care for children or others), severe: feeling sick and vomiting or feeling like you are going to vomit, and unable to perform most daily activities.
Up to 48 hours
Number of participants with first emetic event
Tidsramme: Up to 48 hours
Up to 48 hours
Number of participants with first antiemetic rescue medication
Tidsramme: Up to 48 hours
Up to 48 hours
Participant satisfaction with the prophylactic antiemetic regimens, as assessed by participant satisfaction assessments in the participant diary
Tidsramme: Up to 48 hours
Up to 48 hours
Participant willingness of participants to use the same treatment regimen for future surgical procedures, as assessed by participant satisfaction assessments in the participant diary
Tidsramme: Up to 48 hours
Up to 48 hours
Number of participants with chemistry data outside the reference range
Tidsramme: Up to 48 hours
Up to 48 hours
Number of participants with hematology data outside the reference range
Tidsramme: Up to 48 hours
Up to 48 hours
Safety and tolerability of the antiemetic regimens, assessed by clinical observation (including time to awakening from anesthesia, defined as ability to respond to a verbal command)
Tidsramme: Up to 24 hours
Up to 24 hours
Number of participants with adverse events (AEs) and serious adverse events (SAEs)
Tidsramme: Up to Days 6-14 visit
An AE was defined as any untoward medical occurrence (MO) in a participant temporally associated with the use of a medicinal product (MP), whether or not considered related to the MP and can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with its use. The SAE was any untoward MO that, at any dose, results in death, life threatening, persistent or significant disability/incapacity, results in or prolongs inpatient hospitalization, congenital abnormality or birth defect, that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed in this definition. Refer to the general AE/SAE module for a list of AEs and SAEs.
Up to Days 6-14 visit

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart

1. marts 2006

Primær færdiggørelse (Faktiske)

1. juli 2006

Studieafslutning (Faktiske)

1. juli 2006

Datoer for studieregistrering

Først indsendt

2. juni 2006

Først indsendt, der opfyldte QC-kriterier

2. juni 2006

Først opslået (Skøn)

6. juni 2006

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

23. marts 2017

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

21. marts 2017

Sidst verificeret

1. marts 2017

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • NKT102552

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

Ja

IPD-planbeskrivelse

Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

Studiedata/dokumenter

  1. Datasætspecifikation
    Informations-id: NKT102552
    Oplysningskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
  2. Individuelt deltagerdatasæt
    Informations-id: NKT102552
    Oplysningskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
  3. Annoteret sagsbetænkningsformular
    Informations-id: NKT102552
    Oplysningskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
  4. Formular til informeret samtykke
    Informations-id: NKT102552
    Oplysningskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
  5. Studieprotokol
    Informations-id: NKT102552
    Oplysningskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
  6. Klinisk undersøgelsesrapport
    Informations-id: NKT102552
    Oplysningskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
  7. Statistisk analyseplan
    Informations-id: NKT102552
    Oplysningskommentarer: For additional information about this study please refer to the GSK Clinical Study Register

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .